{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:30:25Z","timestamp":1791955825203,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/INF\/22\/SP33063\/2019"],"award-info":[{"award-number":["BT\/INF\/22\/SP33063\/2019"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["3\/2\/2\/61\/2020-NCD-2020"],"award-info":[{"award-number":["3\/2\/2\/61\/2020-NCD-2020"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.pan.2024.08.009","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T17:21:41Z","timestamp":1723569701000},"page":"1084-1096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular aspects of BRAF and HER2 in prognosis of periampullary carcinoma"],"prefix":"10.1016","volume":"24","author":[{"family":"Apurva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nimisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejaj","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8893-2221","authenticated-orcid":false,"given":"Seneha","family":"Santoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2733-7204","authenticated-orcid":false,"given":"Sundeep Singh","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2024.08.009_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110461","article-title":"Molecular pathways in periampullary cancer: an overview","volume":"100","author":"Apurva","year":"2022","journal-title":"Cell Signal"},{"issue":"Suppl 3","key":"10.1016\/j.pan.2024.08.009_bib2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s12262-019-02053-5","article-title":"Update on management periampullary\/pancreatic head cancer","volume":"83","author":"Tewari","year":"2021","journal-title":"Indian J Surg"},{"key":"10.1016\/j.pan.2024.08.009_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-13-428","article-title":"Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin","volume":"13","author":"Bronsert","year":"2013","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.pan.2024.08.009_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4132\/jptm.2021.01.23","article-title":"Identification of PI3K-AKT signaling as the dominant altered pathway in intestinal type ampullary cancers through whole-exome sequencing","volume":"55","author":"Kumari","year":"2021","journal-title":"Journal of Pathology and Translational Medicine"},{"issue":"4","key":"10.1016\/j.pan.2024.08.009_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0092-8674(88)90571-5","article-title":"Most human carcinomas of the exocrine pancreas contain mutant cK-ras genes","volume":"53","author":"Almoguera","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.pan.2024.08.009_bib6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s13193-017-0645-2","article-title":"Molecular aberrations in periampullary carcinoma","volume":"8","author":"Tewari","year":"2017","journal-title":"Indian Journal of Surgical Oncology"},{"issue":"8","key":"10.1016\/j.pan.2024.08.009_bib7","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1007\/s11605-009-0917-4","article-title":"Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas","volume":"13","author":"Sch\u00f6nleben","year":"2009","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"6","key":"10.1016\/j.pan.2024.08.009_bib8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41416-019-0526-2","article-title":"Exploring the best treatment options for BRAF-mutant metastatic colon cancer","volume":"121","author":"Taieb","year":"2019","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.pan.2024.08.009_bib9","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up)","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.pan.2024.08.009_bib10","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.pan.2024.08.009_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mdy554","article-title":"Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO\u2013ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS","volume":"30","author":"Wu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2024.08.009_bib12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/modpathol.2015.57","article-title":"Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2)","volume":"28","author":"Hechtman","year":"2015","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.pan.2024.08.009_bib13","article-title":"Evaluation of HER2Neu status in periampullary cancers in tertiary care centre in northern India: a three-year retrospective study","volume":"15","author":"Qayoom","year":"2023","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.pan.2024.08.009_bib14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/0046-8177(93)90194-L","article-title":"Overexpression of HER2\/neu oncogene in human pancreatic carcinoma","volume":"24","author":"Yamanaka","year":"1993","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.pan.2024.08.009_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/1097-0142(19930701)72:1<51::AID-CNCR2820720112>3.0.CO;2-O","article-title":"An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas","volume":"72","author":"Satoh","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.pan.2024.08.009_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02788354","article-title":"Overexpression of HER2\/neu oncogene in pancreatic cancer correlates with shortened survival","volume":"17","author":"Lei","year":"1995","journal-title":"Int J Pancreatol"},{"issue":"16","key":"10.1016\/j.pan.2024.08.009_bib17","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"9742","key":"10.1016\/j.pan.2024.08.009_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"45","key":"10.1016\/j.pan.2024.08.009_bib19","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.18632\/oncotarget.27793","article-title":"Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy","volume":"11","author":"Nagarkar","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.pan.2024.08.009_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10549-004-2171-5","article-title":"HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case\u2013control analyses","volume":"89","author":"Millikan","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.pan.2024.08.009_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-010-0965-1","article-title":"Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects","volume":"125","author":"Ma","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.pan.2024.08.009_bib22","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1111\/jcmm.12662","article-title":"Analysis of different HER-2 mutations in breast cancer progression and drug resistance","volume":"19","author":"Sun","year":"2015","journal-title":"J\u00a0Cell Mol Med"},{"issue":"13","key":"10.1016\/j.pan.2024.08.009_bib23","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-22-0283","article-title":"Molecular pathways and mechanisms of HER2 in cancer therapy","volume":"29","author":"Raghav","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2024.08.009_bib24","first-page":"543","article-title":"Periampullary cancers: are there differences?","volume":"81","author":"Sarmiento","year":"2001","journal-title":"Surg Clin"},{"issue":"2","key":"10.1016\/j.pan.2024.08.009_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1477-2574.2009.00140.x","article-title":"Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion","volume":"12","author":"Chen","year":"2010","journal-title":"Hpb"},{"issue":"3","key":"10.1016\/j.pan.2024.08.009_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0046-8177(85)80018-6","article-title":"Morphogenesis and possible precursor lesions of invasive carcinoma of the papilla of Vater: epithelial dysplasia and adenoma","volume":"16","author":"Baczako","year":"1985","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pan.2024.08.009_bib27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2004.09.022","article-title":"Guilty as charged: B-RAF is a human oncogene","volume":"6","author":"Garnett","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pan.2024.08.009_bib28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/carcin\/bgh342","article-title":"The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk","volume":"26","author":"Frank","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pan.2024.08.009_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13205-018-1545-z","article-title":"Frequency of I655V SNP of HER-2\/neu in colorectal cancer: a study from India","volume":"9","author":"Hasan","year":"2019","journal-title":"3 Biotech"},{"issue":"3","key":"10.1016\/j.pan.2024.08.009_bib30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2741\/e838","article-title":"High incidence of BRAFV600 mutation in Indian patients with head and neck cancer","volume":"10","author":"Gauthaman","year":"2018","journal-title":"Frontiers in Bioscience-Elite"},{"issue":"31","key":"10.1016\/j.pan.2024.08.009_bib31","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5194","article-title":"A\u00a0constitutive active MAPK\/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC","volume":"6","author":"Occhi","year":"2015","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.pan.2024.08.009_bib32","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1200\/JCO.2004.02.154","article-title":"Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation","volume":"22","author":"Nagasaka","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.pan.2024.08.009_bib33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2265.2006.02735.x","article-title":"A\u00a0mutation and expression analysis of the oncogene BRAF in pituitary adenomas","volume":"66","author":"Ewing","year":"2007","journal-title":"Clin Endocrinol"},{"issue":"8","key":"10.1016\/j.pan.2024.08.009_bib34","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/cncr.21372","article-title":"Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction","volume":"104","author":"Lewis","year":"2005","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.pan.2024.08.009_bib35","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.7314\/APJCP.2015.16.14.5647","article-title":"Platelet derived growth factor-B and human epidermal growth factor receptor-2 polymorphisms in gall bladder cancer","volume":"16","author":"Mishra","year":"2015","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"10.1016\/j.pan.2024.08.009_bib36","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1093\/nar\/19.19.5452-a","article-title":"G\u00a0to A polymorphism at amino acid codon 655 of the human erbB-2\/HER2gene","volume":"19","author":"Papewalis","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pan.2024.08.009_bib37","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/jnci\/92.5.412","article-title":"Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk","volume":"92","author":"Xie","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.pan.2024.08.009_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cancergen.2022.06.005","article-title":"Analysis of polymorphisms in EGF, EGFR and HER2 genes in pancreatic neuroendocrine tumors (PNETs)","volume":"266","author":"Marinovi\u0107","year":"2022","journal-title":"Cancer Genetics"},{"key":"10.1016\/j.pan.2024.08.009_bib39","first-page":"2021","article-title":"Association of HER1 and HER2 gene variants in the predisposition of colorectal Cancer","author":"Alanazi","year":"2021","journal-title":"Journal of Oncology"},{"key":"10.1016\/j.pan.2024.08.009_bib40","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00404-013-2892-y","article-title":"Polymorphism and overexpression of HER2\/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India","volume":"288","author":"Shanmughapriya","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.pan.2024.08.009_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13205-018-1545-z","article-title":"Frequency of I655V SNP of HER-2\/neu in colorectal cancer: a study from India","volume":"9","author":"Hasan","year":"2019","journal-title":"3 Biotech"},{"issue":"8","key":"10.1016\/j.pan.2024.08.009_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.prp.2012.05.013","article-title":"mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation","volume":"208","author":"Araujo","year":"2012","journal-title":"Pathol Res Pract"},{"issue":"8","key":"10.1016\/j.pan.2024.08.009_bib43","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/cncr.21372","article-title":"Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction","volume":"104","author":"Lewis","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.pan.2024.08.009_bib44","first-page":"251","article-title":"Gastric cancer: classification, histology and application of molecular pathology","volume":"3","author":"Hu","year":"2012","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"4","key":"10.1016\/j.pan.2024.08.009_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153533","article-title":"Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in periampullary adenocarcinoma","volume":"11","author":"Elebro","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pan.2024.08.009_bib46","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ijc.33225","article-title":"Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)","volume":"148","author":"Assenat","year":"2021","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.pan.2024.08.009_bib47","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","article-title":"A\u00a0central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy","volume":"68","author":"Lee-Hoeflich","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.pan.2024.08.009_bib48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.pan.2024.08.009_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","article-title":"HER2-targeted therapies in cancer: a systematic review","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark Res"},{"issue":"13","key":"10.1016\/j.pan.2024.08.009_bib50","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.3390\/ijms22136813","article-title":"Beyond RAS and BRAF: HER2, a new actionable oncotarget in advanced colorectal cancer","volume":"22","author":"Guarini","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.pan.2024.08.009_bib51","doi-asserted-by":"crossref","first-page":"484","DOI":"10.14701\/ahbps.2020.24.4.484","article-title":"Impact of lymph node staging systems inpredicting outcome in patients with ampullary cancer","volume":"24","author":"Saluja","year":"2020","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.pan.2024.08.009_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Molecular biology international"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390324007051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390324007051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T15:35:16Z","timestamp":1731166516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390324007051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1424390324007051"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2024.08.009","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular aspects of BRAF and HER2 in prognosis of periampullary carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2024.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 IAP and EPC. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}